Posted by admin in Prescription Diabetes Drugs on June 30th, 2011

The GOAL lifestyle implementation trial helped individuals at risk for Type 2 diabetes to maintain a reduction in weight, body mass index (BMI), and serum total cholesterol for 36 months, say researchers.

“The GOAL Lifestyle Implementation Trial was designed to replicate results from efficacy trials such as the Diabetes Prevention Study (DPS), under more ‘real world’ conditions with a more modest program delivered by existing health care personnel,” say Pilvikki Absetz (National Institute for Health and Welfare, Helsinki, Finland) and co-investigators.

The team report in the journal Diabetes Care that the statistically significant mean reductions in weight, BMI, and total cholesterol of 1.0 kg, 0.5 kg/m2, and 0.40 mmol/l (15.47 mg/dl), respectively, achieved by the participants at 12 months were maintained at 36 months.

Overall, 12% of individuals who had impaired glucose tolerance (IGT) at baseline developed Type 2 diabetes at 3 years. This is in line with the DPS, in which 9% of those with IGT in the intervention group converted to Type 2 diabetes at study completion compared with 20% of the control group.

The cohort consisted of 352 men and women aged 50??”65 years with a Type 2 diabetes risk score (FINDRISC) of 16.2 and an average BMI of 32.6 kg/m2 at baseline. Of the original 352 participants, 312 attended the measurement session at 1 year and 271 the session at 3 years.

The intervention had the same lifestyle change objectives as the DPS and consisted of six sessions of task oriented sociobehavioral group counseling carried out by nurses over a period of 8 months. There was no other contact with participants apart from follow-up measurements which were taken at 1 and 3 years.

The authors conclude: “Wit

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.